Publications by authors named "A Sioni"
Background: Despite advances in the treatment of oncology patients, therapy-related side effects may lead to premature morbidity. Inflammatory activation that has been linked to cardiovascular disease is crucial for the pathogenesis of both Hodgkin (HL) and non-Hodgkin lymphoma (NHL).
Objectives: The purpose of this study was to assess the vascular effects of chemotherapy in patients with HL and NHL by positron emission tomography/computed tomography with 18-fluorodeoxyglucose (18-FDG PET/CT) and to investigate interactions with systemic inflammation as assessed by circulating inflammatory markers.
Article Synopsis
- Researchers studied how effective new treatments called VRd and DBQ are for patients with a type of blood cancer called primary plasma cell leukemia (pPCL) compared to older treatments.
- They looked at 110 patients and found that those treated with the new treatments had better results, with nearly 83% of them responding well to the treatment.
- Overall, patients using VRd/DBQ lived longer and had fewer complications than those on older treatments, making it the best option for treating pPCL right now.
Article Synopsis
- The study investigated the relationship between lymphoma severity and cardiovascular health, specifically looking at arterial inflammation through FDG uptake in patients with active Hodgkin's and non-Hodgkin's lymphoma.
- Sixty-two chemotherapy-naïve patients were compared to previously treated lymphoma patients to assess metabolic tumor volume and glycolysis associated with arterial fluoride uptake.
- Results showed significant correlations between disease severity and arterial inflammation, with higher FDG uptake in active lymphoma patients compared to controls, particularly in advanced stages of the disease.
Transplant-ineligible relapsed/refractory (rr) diffuse large B-cell lymphoma (DLBCL) patients represent an unmet medical need. Polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate (ADG), with bendamustine- rituximab(BR) has recently gained approval for these patients, both in the USA and Europe, based on the GO29365 phase IIb trial. Real-life data with Pola are extremely limited.
View Article and Find Full Text PDFBackground: Multiple myeloma (MM) patients presenting with anaemia as their sole clinical manifestation are rare and not fully defined.
Methods: Retrospective multi-site study comparing the characteristics and outcome of MM patients with anaemia only with matched patients, presenting with multi-organ disease.
Results: Anaemia-only patients had a higher percentage of bone marrow monoclonal plasma cells group (median 60% [IQR 42-80%] vs.